Fluphenazine is an older typical (first‑generation) antipsychotic, and most of its “phase development” story is historical—long before today’s modern phase-trial structure was used widely. So you’ll usually find it described as having been investigated in early clinical studies (often pre‑marketing) and then later supplemented with formulation/indication studies, rather than a single clean “Phase 1 → Phase 2 → Phase 3” modern package.
That said, here’s the practical way to think about its clinical development phases, based on how these drugs were typically advanced and what later studies often covered:
1) Early/Pre‑marketing development (roughly “Phase 1/2” equivalent)
- Goal: establish basic tolerability, dosing ranges, and preliminary antipsychotic activity.
- Population: small numbers of participants with psychotic symptoms and/or healthy volunteers (depending on the era and protocol).
- Typical endpoints: adverse effects (sedation, extrapyramidal symptoms), early efficacy signals, and tolerability across dose levels.
2) Pivotal efficacy/safety testing (roughly “Phase 2/3” equivalent)
- Goal: confirm antipsychotic efficacy and characterize side‑effect profiles at clinically relevant doses.
- Population: patients with schizophrenia or related psychotic disorders.
- Endpoints (then and now): symptom reduction (e.g., global psychiatric scales), relapse prevention, and safety measures—especially extrapyramidal symptoms (EPS), tardive dyskinesia risk, sedation, and other typical antipsychotic adverse effects.
- Comparator strategy: often included placebo and/or another antipsychotic in that era, though documentation varies.
3) Post‑marketing / formulation development (often “Phase 1/2” type studies)
For fluphenazine specifically, later “development phases” were commonly about:
- Depot (long‑acting injectable) formulations and dosing schedules (e.g., fluphenazine decanoate)
- Bioavailability/tolerability for different salts, concentrations, or injection protocols
- Switching studies between oral and depot dosing regimens (sometimes designed similarly to later phase studies)
- Safety follow‑up (tardive dyskinesia surveillance, long-term tolerability)
4) Indication/label updates
Even if the drug itself wasn’t “re‑approved” from scratch, regulators often add:
- expanded or clarified indications
- dosing guidance
- warnings and risk information as long‑term real‑world data accumulates
---
If you want, I can give you the exact trial/phase details
To do that accurately, I need one clarification because “fluphenazine clinical trials” can mean different things:
1) Do you mean oral fluphenazine or fluphenazine decanoate (depot)?
2) Are you asking for:
- FDA/EMA approval history (dates and pivotal study references), or
- a list of registered clinical trials (e.g., ClinicalTrials.gov), or
- a scientific summary of efficacy/safety evidence by era?
Reply with (1) and (2), and I’ll compile the most relevant “phase development” timeline and study references.